J4 ›› 2011, Vol. 37 ›› Issue (1): 30-34.

Previous Articles     Next Articles

Effects of |combination treatment of rapamycin and |adriamycin on proliferation |and migration of hepatoma cell BEL-7402 and their mechanisms

JIN Li-Peng, WANG Guang-Yi, XIE Shu-Li, LU Guo-Yue   

  1. (Department of Hepatobiliary and Pancreatic Surgery,First Hospital,Jilin University,Changchun 130021,China)
  • Received:2010-07-22 Online:2011-01-28 Published:2011-01-28

Abstract:

Abstract:Objective
To investigate the combination effects of rapamycin(RAPA) and adriamycin  (ADM) on the proliferation and migration of hepatoma cell BEL-7402,and furthermore  analyze the possible mechanisms. Methods The  hepatoma cell BEL-7402 in logarithmic growth phase were  selected as the research object,and  were randomly divided into five groups:blank control group,vehicle group,RAPA group ,ADM group and combination group.The cell proliferation in 6 d in  five groups was detected by MTT,the cyclin D1 mRNA and MMP-2 mRNA expressions in various groups were detected by RT-PCR,and the cyclin D1 protein expression was detected by Western blotting. Results From the 3rd day to the 6th day of the cell culture,the cell proliferation rate in combination group was lower than those in control,vehicle,RAPA and ADM groups(P<0.01).The expression of cyclin D1 mRNA in combination group(0.63)was lower than those  in control(1.02),RAPA(0.77)and ADM(0.76) groups.The expression of MMP-2 mRNA in combination group(0.88)was lower than those in control(1.98),RAPA(1.40) and ADM (1.28) groups.The expression of cyclin D1 protein in combination group(0.33) was lower than those in control(0.92),RAPA(0.75)and ADM (0.74) groups. Conclusion The combination treatment of RAPA and ADM can improve the sensitivity of hepatoma cell BEL-7402 to ADM,the mechanism perhaps lies in the combination of the two drugs can inhibit the expressions of cyclin D1 mRNA,MMP-2 mRNA and cyclin D1 protein more significantly.

Key words: apamycin; adriamycin;hepatoma cell;coordination function;proliferation

CLC Number: 

  • R735.7